Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025

Reuters

2025/10/15

<a href="https://laohu8.com/S/TEM">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025

Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575578237"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575578237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575578237?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575578237","market":"us","top_or_hot":-1,"title":"Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-15 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861559042.SGD","symbol_name":"日兴方舟颠覆性创新基金B SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL6m0dcP:1","article_id":"2575578237","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575578237","pubTimestamp":1760531434,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology  Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer  sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4613":"AI应用软件","TEM":"Tempus AI","BK4611":"AI医疗","BK4121":"生命科学工具和服务"},"translate_title":"Tempus AI宣布将在2025年ESMO大会上展示精准癌症治疗的新临床试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":0.9},"content_text":"Tempus AI Announces New Clinical Trial Findings on Precision Cancer Treatments to Be Presented at ESMO Congress 2025\n    \n\n        Tempus AI Inc. has announced that six abstracts have been accepted for presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place from October 17-21 in Berlin, Germany. Among these, two are oral presentations and four are poster presentations. One of the oral presentations will focus on the efficacy of cabozantinib and nivolumab in Cluster 1/2 metastatic clear cell renal cell carcinoma, with results from the phase II OPTIC RCC trial featuring a novel RNAseq-based biomarker. Another research summary to be presented examines real-world data from 2,173 patients with metastatic castration-sensitive prostate cancer (mCSPC) sequenced using the Tempus xT DNA assay. This analysis found that patients with a high burden of tumor suppressor gene alterations had inferior overall survival outcomes following first-line therapy. These findings will be presented at ESMO Congress 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251015824479) on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}